NCT01702844View on ClinicalTrials.gov

Single Arm on the Tolerability of Weekly Nab-paclitaxel

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 25, 2013

Primary Completion Date

June 23, 2017

Study Completion Date

July 12, 2019

Conditions
Non Small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Nab-Paclitaxel

Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15

Trial Locations (8)

15232

University of Pittsburgh Medical Center, Pittsburgh

19111

Fox Chase Cancer Center, Philadelphia

23114

Bon Secours Virginia Health System, Midlothian

27599

UNC Lineberger Comprehensive Cancer Center, Chapel Hill

27607

Rex Healthcare, Raleigh

44195

Cleveland Clinic, Cleveland

72703

Highlands Oncology Group, Fayetteville

98104

Swedish Cancer Institute, Seattle

Sponsors

Collaborators (1)

Celgene
All Listed Sponsors
collaborator

Celgene

INDUSTRY

lead

UNC Lineberger Comprehensive Cancer Center

OTHER